| |
| |
|
| Insider
Information: |
Friedman Paul A |
| Relationship: |
Director |
| City: |
Palo Lato |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
964,465 |
|
|
Indirect Shares
|
670,540 |
|
|
| Direct
Value |
$53,882,960 |
|
|
|
Indirect Value
|
$139,161,579 |
|
|
| Total
Shares |
1,635,005 |
|
|
| Total
Value |
$193,044,539 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 14.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Incyte Corp |
INCY |
Director |
2020-05-26 |
256,813 |
2020-05-26 |
15,000 |
Premium* |
|
|
Bausch & Lomb, Inc. |
BOL.04 |
Director |
2007-10-26 |
0 |
2004-06-01 |
0 |
Premium* |
|
|
Verastem, Inc. |
VSTM |
Director |
2014-12-24 |
3,000 |
2014-12-24 |
0 |
Premium* |
|
|
Madrigal Pharmaceuticals Inc |
MDGL |
|
2024-04-08 |
185,735 |
2024-04-08 |
655,540 |
Premium* |
|
|
Dare Bioscience Inc |
DARE |
Director |
2017-04-03 |
18,819 |
2016-10-03 |
0 |
Premium* |
|
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2021-07-21 |
0 |
2017-11-29 |
0 |
Premium* |
|
|
Prelude Therapeutics Inc |
PRLD |
Director |
2020-09-29 |
500,098 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
97 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BOL.04 |
Bausch & Lomb, Inc. |
Director |
– • – |
2004-06-01 |
4 |
A |
$62.31 |
$23,491 |
D/D |
377 |
377 |
|
- |
|
| INCY |
Incyte Corp |
Chief Executive Officer |
• • – |
2011-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
409,707 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2015-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,817 |
6,817 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Chief Executive Officer |
• • – |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
143,703 |
143,703 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Chief Executive Officer |
• • – |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
729,066 |
729,066 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Chief Executive Officer |
• • – |
2016-07-22 |
4/A |
A |
$0.00 |
$0 |
D/D |
153,128 |
153,274 |
0 |
- |
|
| DARE |
Dare Bioscience Inc |
Director |
– • – |
2016-10-03 |
4 |
A |
$1.02 |
$3,750 |
D/D |
3,676 |
3,676 |
0 |
- |
|
| DARE |
Dare Bioscience Inc |
Director |
– • – |
2017-01-03 |
4 |
A |
$0.77 |
$3,750 |
D/D |
4,870 |
8,546 |
0 |
- |
|
| DARE |
Dare Bioscience Inc |
Director |
– • – |
2017-04-03 |
4 |
A |
$0.73 |
$7,499 |
D/D |
10,273 |
18,819 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2017-11-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,977 |
1,977 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2018-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,174 |
4,151 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2019-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,520 |
255,531 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,726 |
6,877 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,468 |
10,345 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • – |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282 |
256,813 |
0 |
- |
|
| PRLD |
Prelude Therapeutics Inc |
Director |
– • – |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
D/D |
448,370 |
500,098 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2021-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,495 |
12,840 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Chief Executive Officer |
• • – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
26,668 |
26,668 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2024-04-03 |
4 |
AS |
$242.00 |
$6,718,002 |
D/D |
(27,407) |
185,735 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2024-04-04 |
4 |
AS |
$241.07 |
$4,545,721 |
D/D |
(18,710) |
185,735 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2024-04-05 |
4 |
AS |
$240.10 |
$6,721,081 |
D/D |
(27,613) |
185,735 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
|
– • – |
2024-04-08 |
4 |
AS |
$242.95 |
$6,467,491 |
D/D |
(26,270) |
185,735 |
0 |
% |
|
| BOL.04 |
Bausch & Lomb, Inc. |
Director |
– • – |
2004-06-07 |
4 |
B |
$64.91 |
$24,667 |
D/D |
380 |
380 |
2.39 |
- |
|
| INCY |
Incyte Corp |
Chief Executive Officer |
• • – |
2004-08-16 |
4 |
B |
$5.60 |
$19,658 |
D/D |
3,500 |
421,135 |
2.81 |
- |
|
| BOL.04 |
Bausch & Lomb, Inc. |
Director |
– • – |
2005-03-16 |
4 |
B |
$72.23 |
$36,122 |
D/D |
500 |
880 |
2.39 |
- |
|
97 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
